Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY | BSE:500124

₹6878.65 25.45 (0.37%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

6791.60

Today’s High

6966.00

52W low

5205.60

52W High

6966.00

Open Price

6889.00

Prev. Close

5890.9500

Volume

422278.00

Value

2904702564.70

Fundamentals

Market Cap

114756.30

Price to Earnings

20.60

Price to Book Value

4.10

Dividend Yield

0.60

PE to Growth

0.90

Op Revenue TTM

28011.10

Net Profit TTM

5577.90

Cash From Operating Activity

4543.30

Return on Equity %

19.74

EMA & SMA

Bullish Moving Averages

16

Bearish Moving Averages

0

5Day EMA

6826.4

10Day EMA

6756.6

12Day EMA

6727.7

20Day EMA

6616.9

26Day EMA

6546.4

50Day EMA

6371.6

100Day EMA

6210.4

200Day EMA

5973.1

5Day SMA

6837.6

10Day SMA

6765.2

20Day SMA

6625.4

30Day SMA

6435.2

50Day SMA

6218.7

100Day SMA

6189.6

150Day SMA

6115.5

200Day SMA

5972.9

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

26 Jul, 2024

52.8

Week

56.1

Month

52.3

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

6878.75

PIVOT

First Resistance

6965.90

Second Resistance

7053.15

Third Resistance

7140.30

First Support

6791.50

Second Support

6704.35

Third Support

6617.10

Relative Strength Index

72.58

Money Flow Index

83.22

MACD

181.26

MACD Signal

171.84

Average True Range

139.91

Average Directional Index

37.89

Rate of Change (21)

13.32

Rate of Change (125)

21.22

Commodity Channel Index

123.9

Williams %R

-16.3

BETA

1 Month

0.33

3 Month

0.34

1 Year

0.38

3 Year

0.03

PRICE CHANGE ANALYSIS

↑ 3.66%

1 Week

Low

High

6580

6966

↑ 13.32%

1 Month

Low

High

5995

6966

↑ 10.02%

3 Months

Low

High

5600

6966

↑ 17.47%

6 Months

Low

High

5600

6966

↑ 25.62%

1 Year

Low

High

5205.55

6966

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Graph
Total Qtr Revenue cr 5317.50 4330.60 5061.80 5670.90 4668.80 3949.00 4998.30 4034.00 3783.40 3542.60 3941.50 3619.70 3432.30
Operating Expenses Qtr 3700.20 3446.70 3209.60 3209.60 3488.80 3221.50 3077.50 3051.10 2989.00 2865.60 3075.10 2871.60 2747.80
Operating Profit Qtr 1378.60 656.30 1629.10 2227.70 1061.10 675.10 1802.80 579.50 669.90 614.00 748.30 561.90 602.90
EBIDT Qtr Cr 1591.30 883.90 1852.20 2461.30 1175.90 726.50 1920.80 982.90 784.60 677.00 866.40 748.10 684.50
Depreciation Qtr 246.20 246.40 245.80 237.20 236.70 238.80 226.20 221.50 205.20 205.40 206.60 197.10 210.70
Net Profit Qtr 1034.80 475.20 1192.60 1639.40 672.40 324.60 1116.30 499.50 419.70 341.10 449.00 413.40 311.50
Basic EPS Qtr 62.14 28.55 71.68 98.66 40.49 19.54 67.25 30.10 25.29 20.55 27.07 24.94 18.78
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 20346.10 17553.80 14887.20 14150.20 12593.60
Operating Expenses Annual Cr 13557.40 12747.70 11811.10 10212.30 8980.80
Operating Profit Annual 5926.40 4214.80 2594.10 3136.80 2869.60
Operating Profit Margin Annual % 29.13 24.01 17.43 22.17 22.79
Total Expenses Annual Cr 14554.80 13687.80 12663.40 11094.00 9817.80
EBIDT Annual Cr 6788.70 4806.10 3076.10 3937.90 3612.80
EBIDT Annual margin % 33.37 27.38 20.66 27.83 28.69
Depreciation 975.60 923.20 814.30 835.00 789.20
PAT Before ExtraOrdinary Items Annual Cr 4342.00 2612.80 1623.20 2186.40 2937.70
Net Profit Annual 4342.00 2612.80 1623.20 2186.40 2937.70
Basic EPS Annual 260.95 157.37 97.85 131.84 177.23
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 24240.80 20474.20 18336.20 16983.70 15191.90
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 580.40 460.90 114.30 85.60 103.40
Total Current Liabilities Annual Cr 5538.10 4439.70 6045.10 4560.30 4180.50
Total Capital Plus Liabilities Annual Cr 30359.30 25374.80 24495.60 21629.60 19475.80
Fixed Assets Annual 8800.10 8119.70 7350.80 6745.10 4845.70
Total Non Current Assets Annual 12543.40 11586.50 11012.00 10685.40 9369.10
Total Current Assets Annual 17815.90 13788.30 13483.60 10944.20 10106.70
Total Assets Annual 30359.30 25374.80 24495.60 21629.60 19475.80
Contingent Liabilities plus Commitments Annual Cr 1763.60 830.20 827.40 1062.80 1068.60
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 3449.70 5052.90 1338.70 3514.20 1839.20
Cash from Investing Activity Annual -3430.30 -3447.60 -2038.00 -1458.00 -1689.20
Cash from Financing Annual Activity 68.10 -2696.90 505.50 -794.30 -224.10
Net Cash Flow Annual 87.50 -1091.60 -193.80 1261.90 -74.10
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 1453.29 1228.94 1101.93 1020.65 914.07
ROE Annual % 17.91 12.76 8.85 12.87 19.33
ROCE Annual % 23.41 18.54 12.25 18.17 18.46
Total Debt to Total Equity Annual 0.03 0.00 0.12 0.07 0.07
EBDIT Annual Margin % 34.84 28.33 21.35 29.49 30.48
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Graph
Total Qtr Revenue cr 7311.30 7453.00 7217.60 6931.90 6453.70 6848.50 6372.60 6086.80 5596.80 5394.10 5992.40 5053.00 4850.80
Operating Expenses Qtr 5299.90 5213.70 4888.80 4694.70 4727.30 4837.90 4430.40 4291.70 4282.00 4117.90 4427.10 4210.60 3713.50
Operating Profit Qtr 1831.20 2023.10 2008.30 2062.10 1533.90 1938.50 1898.90 941.20 451.00 1215.70 1359.80 734.50 1053.20
EBIDT Qtr Cr 2028.70 2239.30 2323.30 2236.10 1672.40 1997.20 1939.70 1795.10 572.90 1271.50 1565.30 842.40 1135.80
Depreciation Qtr 367.70 373.50 375.50 353.30 315.50 323.70 309.20 301.80 293.00 294.20 294.10 283.90 308.80
Net Profit Qtr 1309.80 1380.90 1482.20 1405.00 960.10 1243.90 1114.20 1189.00 97.00 709.30 995.80 380.40 557.30
Basic EPS Qtr 78.66 82.94 89.09 84.55 57.79 74.91 67.13 71.64 5.84 42.75 60.03 22.95 33.61
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 28905.40 25725.20 22029.60 19338.90 18137.60
Operating Expenses Annual Cr 20078.00 18320.70 17777.50 15177.60 15046.60
Operating Profit Annual 7933.10 6349.00 3767.70 3869.90 2470.40
Operating Profit Margin Annual % 27.45 24.68 17.10 20.01 13.62
Total Expenses Annual Cr 21719.10 19713.70 19038.50 16503.40 16308.00
EBIDT Annual Cr 8827.40 7404.50 4252.10 4161.30 3091.00
EBIDT Annual margin % 30.54 28.78 19.30 21.52 17.04
Depreciation 1470.00 1250.20 1165.20 1228.80 1163.10
PAT Before ExtraOrdinary Items Annual Cr 5563.20 4470.30 2112.20 1903.60 1969.90
Net Profit Annual 5577.90 4507.30 2182.50 1951.60 2026.00
Basic EPS Annual 335.22 271.47 131.21 117.34 121.99
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 28254.80 23286.10 19212.40 17641.70 15598.80
Minority Interest Liability Annual Cr 0.00 0.00 0.00 0.00 0.00
Total Non Current Liabilities Annual Cr 1021.00 426.90 768.70 871.30 412.40
Total Current Liabilities Annual Cr 9588.00 8572.10 9765.80 8103.80 7214.10
Total Capital Plus Liabilities Annual Cr 38863.80 32285.10 29746.90 26616.80 23225.30
Fixed Assets Annual 11294.80 9701.80 8867.60 9210.90 7894.10
Total Non Current Assets Annual 14058.50 11859.60 11964.60 12066.50 10626.20
Total Current Assets Annual 24805.30 20425.50 17782.30 14550.30 12599.10
Total Assets Annual 38863.80 32285.10 29746.90 26616.80 23225.30
Contingent Liabilities plus Commitments Annual Cr 2091.80 997.40 936.80 1077.40 1040.60
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 4543.30 5887.50 2810.80 3570.30 2984.10
Cash from Investing Activity Annual -4028.30 -4137.30 -2638.70 -2266.00 -492.30
Cash from Financing Annual Activity -376.30 -2686.10 -242.20 -29.80 -2515.90
Net Cash Flow Annual 138.70 -935.90 -70.10 1274.50 -24.10
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 1693.93 1397.72 1154.59 1060.20 938.56
ROE Annual % 19.74 19.35 11.35 11.06 12.98
ROCE Annual % 25.13 25.95 15.44 15.84 12.04
Total Debt to Total Equity Annual 0.06 0.05 0.16 0.15 0.11
EBDIT Annual Margin % 31.51 30.01 19.73 21.84 17.64
Name Holding Percent Holding Id Pledged % Locked %
HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF 1.75 89016255 - -
ICICI PRUDENTIAL VALUE DISCOVERY FUND 1.17 89016257 - -
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 2.53 89016263 - -
Name Holding Percent Holding Id Pledged % Locked %
G V PRASAD 11.52 89016238 0 0
SATISH REDDY KALLAM 9.61 89016239 0 0
KALLAM SATISH REDDY HUF 3.31 89016240 0 0
GUNUPATI VENKATESWARA PRASAD HUF 1.52 89016241 0 0
SAMRAJYAM REDDY KALLAM 0.67 89016242 0 0
Name Holding Percent Holding Id
HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF 1.75 89016255
SBI NIFTY INDEX FUND 1.29 89016256
ICICI PRUDENTIAL VALUE DISCOVERY FUND 1.17 89016257
MIRAE ASSET NIFTY INDIA MANUFACTURING ETF 1.11 89016258
NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND 1.02 89016259
FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND 2.32 89016269
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND 5.52 89016261
J P Morgan Chase Bank NA 14.59 89016266
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 2.53 89016263
Name Holding Percent Holding Id
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Jul 16, 2024 40 FINAL - Equity Share
Jul 11, 2023 40 FINAL - Equity Share
Jul 11, 2022 30 FINAL - Equity Share
Jul 09, 2021 25 FINAL - Equity Share
Jul 13, 2020 25 FINAL - Equity Share
Jul 15, 2019 20 FINAL - Equity Share
Jul 16, 2018 20 FINAL - Equity Share
Jul 17, 2017 20 FINAL - Equity Share
Jul 18, 2016 20 FINAL - Equity Share
Jul 10, 2015 20 FINAL - Equity Share
Jul 11, 2014 18 FINAL - Equity Share
Jul 12, 2013 15 FINAL - Equity Share
Jun 28, 2012 13.75 FINAL - Equity Share
Jun 30, 2011 11.25 FINAL - Equity Share
Jul 02, 2010 11.25 FINAL - Equity Share
Jul 03, 2009 6.25 FINAL - Equity Share
Jul 04, 2008 3.75 FINAL - Equity Share
Jul 06, 2007 3.75 FINAL - Equity Share
Jul 07, 2006 5 FINAL - Equity Share
Jul 07, 2005 5 FINAL - Equity Share
Jul 13, 2004 5 FINAL - Equity Share
Aug 08, 2003 5 FINAL - Equity Share
Aug 08, 2002 - FINAL - Equity Share
Nov 08, 2001 - INTERIM Nov 26, 2001 Equity Share
Jun 18, 2001 - FINAL - Equity Share
Sep 07, 2000 - FINAL - Equity Share
Ex-Date Split Ratio Record Date
Oct 10, 2001 10:5 2001-10-25
Ex-Date Purpose Notes
Jul 27, 2024 Quarterly Results & Stock Split -
May 07, 2024 Audited Results & Final Dividend -
Jan 30, 2024 Quarterly Results -
Oct 27, 2023 Quarterly Results -
Jul 26, 2023 Quarterly Results -
May 10, 2023 Audited Results & Final Dividend -
Jan 25, 2023 Quarterly Results -
Oct 28, 2022 Quarterly Results -
Jul 28, 2022 Quarterly Results -
May 19, 2022 Audited Results & Final Dividend -
Jan 28, 2022 Quarterly Results -
Oct 29, 2021 Quarterly Results -
Jul 27, 2021 Quarterly Results -
May 14, 2021 Audited Results & Final Dividend -
Jan 29, 2021 Quarterly Results -
Oct 28, 2020 Quarterly Results -
Jul 29, 2020 Quarterly Results -
May 20, 2020 Audited Results & Final Dividend (Revised)
May 13, 2020 Audited Results & Final Dividend -
Mar 27, 2020 Others Inter alia, to consider and approve Raising of funds through issuance of Commercial Papers.
Jan 27, 2020 Quarterly Results -
Nov 01, 2019 Quarterly Results -
Jul 29, 2019 Quarterly Results -
May 17, 2019 Audited Results & Final Dividend -
Feb 01, 2019 Quarterly Results -
Oct 26, 2018 Quarterly Results -
Jul 26, 2018 Quarterly Results -
May 22, 2018 Audited Results & Dividend -
Jan 25, 2018 Quarterly Results -
Oct 31, 2017 Quarterly Results -
Jul 27, 2017 Quarterly Results -
May 12, 2017 Audited Results & Dividend -
Feb 04, 2017 Quarterly Results -
Oct 25, 2016 Quarterly Results -
Jul 26, 2016 Quarterly Results -
May 12, 2016 Audited Results & Dividend -
Feb 17, 2016 Buy Back of Shares -
Feb 09, 2016 Quarterly Results -
Oct 29, 2015 Quarterly Results -
Jul 30, 2015 Quarterly Results -
May 12, 2015 Audited Results & Final Dividend -
Jan 29, 2015 Quarterly Results -
Oct 29, 2014 Quarterly Results -
Jul 30, 2014 Quarterly Results -
May 13, 2014 Audited Results & Dividend -
Feb 11, 2014 Quarterly Results -
Oct 31, 2013 Quarterly Results -
Jul 30, 2013 Quarterly Results -
May 14, 2013 Audited Results & Dividend -
Feb 14, 2013 Quarterly Results -
Oct 30, 2012 Quarterly Results -
Jul 19, 2012 Quarterly Results -
May 11, 2012 Audited Results & Dividend -
Feb 03, 2012 Quarterly Results -
Oct 25, 2011 Quarterly Results -
Jul 20, 2011 Quarterly Results -
May 13, 2011 Audited Results & Dividend -
Jan 25, 2011 Quarterly Results -
Oct 23, 2010 Quarterly Results -
Jul 22, 2010 Quarterly Results -
May 06, 2010 Audited Results, Dividend & ESOP To grant of 16,800 stock options, exercisable at par value of Rs. 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS, 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007".
Mar 31, 2010 Issuance of Bonus Debentures For issuance of bonus debentures to Shareholders of the Co. from its General Reserves built from undistributed profits, The allotment of debentures will account for an amount not exceeding Rs. 520 Cr.
Jan 20, 2010 Quarterly Results -
Oct 23, 2009 Quarterly Results -
Jul 21, 2009 Quarterly Results -
May 18, 2009 Audited Results, Dividend & Others To grant of 9,000 stock options, exercisable at par value of Rs 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007".
Jan 20, 2009 Quarterly Results -
Oct 23, 2008 Quarterly Results & Amalgamation To consider a Scheme of Amalgamation in terms of which Periecan Pharma Pvt. Ltd, a wholly owned subsidiary of the Company will be amalgamated with Dr. Reddy's Laboratories Ltd.
Jul 21, 2008 Quarterly Results -
May 20, 2008 Audited Results & Dividend -
Jan 25, 2008 Quarterly Results -
Oct 24, 2007 Quarterly Results -
Jul 23, 2007 Quarterly Results -
May 18, 2007 Audited Results & Dividend -
Jan 22, 2007 Quarterly Results -
Oct 27, 2006 Quarterly Results -
Jul 27, 2006 Quarterly Results -
May 31, 2006 Accounts & Dividend -
Jan 24, 2006 Quarterly Results -
Oct 29, 2005 Quarterly Results -
Jul 26, 2005 Quarterly Results -
May 06, 2005 Accounts & Dividend -
Jan 31, 2005 Quarterly Results -
Oct 26, 2004 Quarterly Results -
Jul 27, 2004 Quarterly Results -
Jan 30, 2004 Quarterly Results -
Oct 28, 2003 Quarterly Results -
Jul 31, 2003 Quarterly Results -
May 30, 2003 Accounts & Dividend -
Jan 28, 2003 Quarterly Results -
Oct 24, 2002 Quarterly Results -
Jul 31, 2002 Quarterly Results -
Jun 04, 2002 Accounts & Dividend -
Mar 04, 2002 Interim Dividend -
Jan 29, 2002 Quarterly Results -
Oct 31, 2001 Quarterly, H.Y. Results & I. Dividend -
Jul 31, 2001 Quarterly Results & Others Stock Split & Employees Stock Option Plan
May 30, 2001 Accounts & Dividend -
Jan 30, 2001 Quarterly Results -
Oct 30, 2000 Quarterly Results -
Jul 28, 2000 Quarterly Results -
Mar 23, 2000 Interim Dividend and Issue of ADS -
Mar 06, 2000 Merger -
Oct 20, 1999 Quarterly Results -
Jul 29, 1999 Quarterly Results -
Apr 19, 1999 Accounts & Dividend -
Jan 30, 1999 Quarterly Results -
Oct 21, 1998 Quarterly Results -
Apr 27, 1998 Accounts & Dividend -
May 17, 1997 Accounts & Dividend. -
Ex-Date Bonus Ratio Record Date
Aug 28, 2006 1:1 2006-08-29
Bigul
25 Jul 2024

Dr Reddy's Labs Q1 Preview: Market share loss in products to drag profits

 Indian drugmaker, Dr Reddy's Laboratories is all set to deliver its financial performance for the first quarter of financial year 2024-25 (Q1FY25) on Saturday, July 27, 2024
Bigul
24 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Schedule of Analyst / Institutional Investor Meetings
Bigul
24 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

 Sale of shares of wholly owned subsidiary company
Bigul
23 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Update on board meeting

 DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2024 ,inter alia, to consider and approve Update on board meeting
Bigul
18 Jul 2024

Dr. Reddy's Laboratories joins race to bring new GERD drug to India

 Dr. Reddy's will market Vonoprazan tablets under its own brand Vono, and it will be available in two strengths, 10 mg and 20 mg
Bigul
18 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release
Bigul
12 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI LODR Regulations, 2015

 Disclosure under Regulation 30 of SEBI LODR Regulations, 2015
Bigul
11 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Issue of Letter of confirmation in lieu of share certificate(s) reported lost/ misplaced
Bigul
10 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Loss of Share Certificate(s)
Bigul
10 Jul 2024

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Earnings Call notification for Q1 FY 2025
See all News

FAQs

The latest market price of Dr. Reddy's Laboratories Ltd. on NSE was Rs. 6878.65 as of today.

The opening share price of Dr. Reddy's Laboratories Ltd. was Rs. 6889.00 as of today.

The 52-week high share price of Dr. Reddy's Laboratories Ltd. was Rs. 6966.00.

The 52 week low share price of Dr. Reddy's Laboratories Ltd. was Rs. 5205.60.

Please find Corporate actions section for more details.

The PE ratio of Dr. Reddy's Laboratories Ltd. is 0.90. Please refer to the Fundamentals section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Dr. Reddy's Laboratories Ltd. was on 2024-07-16 for Rs. 40 per share. According to today’s share price, the dividend yield of Dr. Reddy's Laboratories Ltd. stands at 0.60. Please refer to the Corporate Actions section for further details.

The latest bonus issue declared by Dr. Reddy's Laboratories Ltd. was as of 2006-08-28. The bonus ratio declared in this issue was 1:1. Please refer to the Corporate Actions section for further details.

The latest split issue declared by Dr. Reddy's Laboratories Ltd. was as of 2001-10-10. The split ratio declared in this issue was 10:5. Please refer to the Corporate Actions section for further details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Dr. Reddy's Laboratories Ltd..

Close

Let's Open Free Demat Account